Skip to main content
OpenTrials
Completed

NCT Number: NCT01310335

Effect of Whole-Body Vibration on Plasma Sclerostin Level

The aim of this study is to investigate effect of whole-body vibration on plasma sclerostin level in healthy young adult women.

Fifteen healthy young adult women are planned to include in this study. All cases will be trained on a whole-body vibration (WBV) platform (Power Plate) 5 times a week for one week period. Training duration will be short at the beginning but progressed slowly.

The amplitude of vibration will be 2 mm and the frequency of the vibration will be 40 Hz. The subjects will be asked to report negative side effects or adverse reactions in their training diary.

Previbration and postvibration (just after, 10.minute and 30.minute) levels of plasma sclerostin will be measured on first, second and fifth day of experiment. Sclerostin levels will be measured by human sclerostin ELISA kit.

Completed

Looking for future studies?

Notify Me

Key information

Age range

20 year–40 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Bagcilar Training & Research Hospital

Istanbul, Turkey (Türkiye)

About this study

Whole-body vibration has a strong osteogenic effect. The cyclic mechanical loading to the bone stimulates the osteocytes.

Sclerostin, the protein product of the SOST gene, is an osteocyte-specific cysteine knot-secreted glycoprotein that is a potent inhibitor of bone formation. Sost/sclerostin levels have been reported to be reduced by mechanical stimulation.

The aim of this study is to investigate effect of whole-body vibration on plasma sclerostin level in healthy young adult women.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy women,
  • Women with ages varying between 20 and 40 years
  • Right-handed women

Exclusion criteria

  • Lower extremity problems
  • Orthopedic problems: shortness of legs, congenital anomalies, etc.
  • Joint disease (arthritis, joint prosthesis, etc.)
  • Other painful pathologies in the lower extremities (fractures, tendinitis,bursitis, etc.)
  • Circulation problems in the lower extremities
  • Dorsolumbar diseases: Vertebral fract, disc hernias, spondylodiskitis, etc.
  • Systemic disease cases
  • Systemic bone disease: osteoporosis, osteomalacia, Paget's disease
  • Hypertension (>135 mmHg systolic, >85 mmHg diastolic)
  • Heart dis.(coronary dis, conduction/rhythm prob, cardiac pacemaker)
  • Infectious diseases
  • Endocrine diseases (Diabetes mellitus etc)
  • Neurological diseases (CNS problems, peripheral neuropathy)
  • Menstrual cycle disorders, amenorrhea, lactation, oral contraceptive use
  • Cases during the ovulatory period (11-16th day of menses)
  • Obesity (BMI >30 kg/m2) or low BMI (BMI <20 kg/m2)
  • Vertigo
  • Cognitive function disorders
  • Women whose blood samples were not taken in the time planned
  • Women whose blood samples hemolyzed

Treatment and study plan

whole-body vibration (WBV)

Device

All cases will be trained on a whole-body vibration (WBV) platform (Power Plate) 5 times a week for one week period.

Other names: Cyclic mechanical loading

Primary outcomes

  1. Plasma Sclerostin Level

    Time frame: 1 month

    Change of plasma sclerostin level with whole-body vibration

Sponsors and collaborators

Lead sponsor

Bagcilar Training and Research Hospital

Other Gov

Registry information

Official study title

Effect of Whole-Body Vibration on Plasma Sclerostin Level in Healthy Young Adult Women

Acronym: WBV-SCL

Important dates

Study start
2011
Primary completion
2011
Study completion
2011
First posted
Mar 8, 2011
Registry last updated
Feb 25, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.